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In many regions of the nervous system, the combinatorial action of transcriptional factors speciﬁes the
individual fate of neuronal subtypes. Contrary to this, we report that a single transcriptional factor
controls a phenotype shared by different subtypes of neurons, namely the expression of a neurotrophic
factor receptor in the spinal cord. Along the dorsoventral axis of the chick embryo spinal cord, the
expression pattern of a speciﬁc receptor for glial cell line derived-neurotrophic factor (GDNF family of
receptors a1: GFRa1) was related to that of two basic helix-loop-helix (bHLH) transcriptional factors
(NeuroM and Neurogenin2: Ngn2). In ovo electroporation in the chick embryo revealed that the
overexpression of NeuroM alone was sufﬁcient to induce ectopic GFRa1 expression without overt
neuronal differentiation, whereas the suppression of NeuroM activity resulted in the speciﬁc loss of
GFRa1 expression, indicating that NeuroM may act as a differentiation factor for GFRa1 expression.
Ngn2 overexpression was also sufﬁcient to induce precocious GFRa1 expression. However, the forced
expression of both obligate suppressor and activator forms of Ngn2 also induced aberrant GFRa1
expression. Thus, any deviation from an optimum level of Ngn2 expression resulted in aberrant GFRa1
expression. Consistent with this, manipulation of Ngn2 expression levels by other bHLH factors also
resulted in ectopic GFRa1 expression. For example, the downregulation by Ascl1 and the upregulation
by Ptf1a induced ectopic GFRa1 expression, irrespective of endogenous expression patterns of Ascl1
and Ptf1a (Ascl1/Ptf1) in the spinal cord. The suppression of Ascl1/Ptf1a activities abolished Ngn2 and
GFRa1 expression, even in Ascl1/Ptf1a-negative regions. These data indicate the presence of a distinct
regulatory sequence for a determinant of GFRa1 expression, in which Ascl1/Ptf1a may competitively
intervene to stochastically modulate default Ngn2 expression levels. Thus, Ngn2 together with NeuroM
serves as readout to regulate GFRa1 expression, which occurs in multiple subtypes of spinal neurons.
& 2012 Elsevier Inc. All rights reserved.Introduction
Subsets of developing neurons acquire an appropriate collec-
tion of functional proteins such as the surface adhesion mole-
cules, neurotransmitter-synthesizing enzymes and receptors, ion
channel molecules, etc. In the developing nervous system, distinct
subsets of neurons express unique combinations of neurotrophic
factor receptors. This differential expression of neurotrophic
factor receptors is critical for the proper development of the
nervous system, because neurotrophic factors and cognate recep-
tors regulate many aspects of neural development such as
differentiation, survival, process outgrowth, and plasticity. A
well-known example of such differential expression is the Trkll rights reserved.neurotrophin receptor in spinal dorsal root ganglion cells: TrkA
and TrkC are respectively expressed in the small- and large-sized
neurons in the spinal ganglia, and selectively mediate the survival
of corresponding neurons (Snider, 1994).
The four speciﬁc receptors for another neurotrophic factor
family, glial cell line-derived neurotrophic factor (GDNF), the
GDNF family of receptors a (GFRa1-4), are also differentially
expressed in various types of neurons in both the central and
peripheral nervous system. GDNF signaling through GFRa1 recep-
tor is constantly required in speciﬁc subpopulations of neuronal
cells for various aspects of neuronal development (Paratcha and
Ledda, 2008). In the initial phases of the neural development,
GFRa1 is necessary for the differentiation and migration of a
subpopulation of cortical inhibitory interneurons (Pozas and
Iba´n˜ez, 2005; Canty et al., 2009). Gene-knockout studies of GFRa1
have also demonstrated their crucial roles in later phases of
neural development: GFRa1 is required for the survival of distinct
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of speciﬁc subpopulation of motoneurons (Airaksinen et al., 1999;
Garces et al., 2000; Airaksinen and Saarma, 2002; Gould et al.,
2008); GDNF and GFRa1 are also necessary to establish the correct
innervation pattern between a speciﬁc motoneuron group and its
peripheral target (Haase et al., 2002; Vrieseling and Arber, 2006);
and neuronal cell adhesion induced by GDNF- GFRa1-interaction
promotes synapse formation (Ledda et al., 2007). Despite the
increased understanding of signiﬁcant developmental roles of GFRa,
little is known about regulatory mechanisms for the selective
expression of neurotrophic factor receptors including GFRa in
particular subsets of neurons. Originally, GDNF was identiﬁed as a
potent neurotrophic factor for dopaminergic neurons in the mid-
brain (DA neurons), which are selectively lost in Parkinson’s disease
(Lin et al., 1993). Genetic deletion of the GFRa1 gene results in
degenerative changes of DA neurons and increasing vulnerability to
toxic insult during aging (Boger et al., 2008; Zaman et al., 2008).
Despite the crucial role of GFRa1 for the survival of DA neurons, the
mechanism for regulation and maintenance of GFRa1 expression in
the nervous system is unknown. Understanding the embryonic
regulatory mechanism for GFRa1 expression could provide new
insights into the etiology of Parkinson’s disease.
Candidate molecules for regulating differential expression of the
GFRa1 receptor are basic helix-loop-helix (bHLH) transcriptional
factors. In vertebrates, a large number of bHLH transcriptional
factors are expressed in distinct populations of neuronal progenitors
and induce the differentiation of different subtypes of neurons
(Bertrand et al. 2002). For example, two major subtypes of cortical
neurons, GABAergic inhibitory interneurons and glutamatergic pro-
jection neurons, are respectively produced from ventral and dorsal
forebrain, where Ascl1 and Neurogenin2 (Ngn2) are expressed in
complementary fashion. Ascl1 deterministically regulates the pro-
duction of GABAergic interneurons in the ventral telencephalon,
whereas Ngn2 permissively regulates that of glutamatergic neurons
in the dorsal telencephalon (Fode et al., 2000). However, the
ventricular layer in the ventral forebrain encompasses multiple
microdomains, which are deﬁned by the combinatorial expression
pattern of various homeodomain transcriptional factors (Sussel
et al., 1999; Puelles and Rubenstein, 2003). After the GABAergic
phenotype is speciﬁed by Ascl1, subtypes of cortical interneurons
that share the GABAergic phenotype are generated from speciﬁc
microdomains in the ventral forebrain according to a combinatorial
code of homeodomain-containing transcriptional factors (Wonders
and Anderson, 2006; Gelman and Marı´n, 2010). Thus, stepwise
speciﬁcation ensures coupling a shared neurotransmitter subtype,
which is controlled by a single bHLH factor, with a region-speciﬁc
neuronal subtype identity, which is controlled by a combinatorial
code of a different class of transcriptional factors (Ma, 2006).
The ventricular layer of early embryonic spinal cord is also
subdivided into microdomains, which generate distinct subtypes
of neurons along the dorsoventral axis, according to a combina-
torial expression pattern of transcriptional factors (Jessell, 2000;
Caspary and Anderson, 2003; Guillemot et al., 2007; Sugimori
et al., 2007). A variety of bHLH transcriptional factors are
expressed in the multiple microdomains of the spinal cord and
have been shown to regulate local production of neuronal sub-
types, together with regionally expressed co-factors (Mizuguchi
et al., 2001; Novitch et al., 2001; Sugimori et al., 2007). However,
unlike in the forebrain where a single bHLH transcriptional factor
regulates the differentiation of a neurotransmitter phenotype
shared by multiple subtypes of neurons, it is unknown whether
a bHLH factor may also control the differentiation of a particular
neuronal feature shared by the different subclasses of neurons in
the spinal cord. This is largely owing to the lack of information as
to how unique neuronal phenotypes relate to the overall expres-
sion pattern of a particular bHLH factor in the spinal cord. In aprevious study of the expression pattern of GFRa in the spinal
cord at early developmental stages, we noticed a close relation-
ship in the expression patterns between GFRa1 and NeuroM, or
between GFRa1 and Ngn2 (Homma et al., 2003). These simila-
rities in expression patterns suggest that NeuroM and Ngn2 may
be involved in the regulation of GFRa1 expression. Based on this
observation, we have now explored the regulatory role of Neu-
roM, Ngn2 and related bHLH factors in GFRa1 expression using in
ovo electroporation in the chick embryo.Materials and Methods
Embryos and electroporation
Retrovirus-free fertilized eggs were purchased from Takeuchi
Farm (Nara, Japan). The eggs were incubated in the laboratory at
37 1C and 60% relative humidity. The Hamburger and Hamilton
(1951) stage series (HH stage) was used for age determination of
embryos.
Electroporation was carried out in prospective lumbar spinal
cord at HH stage 14. The concentration of plasmid was 0.5 mg/ml
in saline. Electroporation conditions were 20 mV, 50 msec dura-
tion, 150 msec intervals, for 5 times with electrodes 2 mm apart.
Trace amounts of pEGFP-N1 vector (Clontech) were sometimes
mixed in the plasmid solution to monitor electroporation
(0.005 mg/ml at ﬁnal concentration).
cDNA template
pAcGFP1-Nuc vector (Clontech) was used as a template for
nuclear-localized GFP (Nuc-GFP) cDNA. Complementary DNA
template of NeuroM was generous gift from Dr. Ballivet
(Roztocil et al., 1997). Neurogenin2 (Ngn2) cDNA was generous
gift from Dr. Anderson (Perez et al., 1999). Ret receptor tyrosine
kinase cDNA was kindly provided by Dr. Costantini (Schuchardt
et al., 1995). The coding regions in full length of chick GFRa1,
GFRa2, GFRa4, achaete-scute homolog 1 (Ascl1), and engrailed1
were isolated by PCR using the ﬁrst strand cDNA reverse-
transcribed from poly(A)–RNA derived from chick embryos at
HH stage 17. Primer pairs used for the template isolation were
50–ATGTTCCTCGCGCTCCTCTACTTGGCTCTG-30 and 50–GCTACAA-
GACGACTGATGAGCTTAGG-30 for GFRa1, 50–ATGATTTTGGCCTT-
CTGCATCGTCCTC-30 and 50–CTATAGCAGCTTCAGCAGCACAATGGG
CAC-3 for GFRa2, 50–ATGAGGGGCATCCTCTACTTCTGCACGCT-
GATCC-30 and 50–TCACATCATGAAGTGGCTCAGCACAGCAAGAG-30
for GFRa4, 50–ATGGCCAGCGGCAGCCCCGCCGGGATGGCCAG-30
and 50–TCAGAACCAGCTGGTGAAGTCGAGCAGCTCCTG-30 for Ascl1,
and 50–ATGGAAGAGCCGCCGGAGGGGCACGGCCACC-30 and 50–
TCACTCGCTCTCCTCTTTGTCCTGCACCGTGGTGG-30 for engrailed1.
Primer pairs used for the isolation of partial cDNA sequences
of chick Ptf1a and Delta1 used for in situ hybridization were
50–CGAGGCGGAGCTGCAGCAGCTGCGGCAGGCGGCC-30 and 50–
TCACGGCACGAAGCCGAGGGGGGGTTCGTTCTCG-30 for Ptf1a, and
50–CAGTACTGCACTGAGCCGATTTGCTTGCCT-30 and 50–CACTGC-
GATCCAGGGAAACTGGCTGTTCTG-30 for Delta1. The sequence
information used for template isolation was derived from BBSRC
chick EST database and NCBI nucleotide database.
We have not been able to isolate the full length chick Ptf1a
cDNA and have used mouse Ptf1a sequence for the construction.
Full length coding region of mouse Ptf1a was isolated by PCR
from the E10 mouse ﬁrst strand cDNA using the primer pair
of 50–ATGGACGCCGTACTCCTGGAGCACTTCCCCGGGGGCC-30 and
50–TCAGGACACAAACTCAAAGGGTGGTTCGTTCTCTATGTTGTCG-30.
Complementary DNA fragment of the herpesvirus VP16 acti-
vator domain was isolated from the genomic DNA of human
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of Bacteriology in our institute, using primers, 50–CTGTCGACG
GCCCCCCCGACCGATGTCAGCCTGG-30 and 50–CTACCCACCGTACT-
CGTCAATTCCAAGGGCATCGG-30.
The PCR products were cloned into pCRII TOPO cloning vector
(Invitrogen). Correct DNA sequences of obtained PCR products
were conﬁrmed using ABI 3100 sequencer.
Expression vector construction
We used the avian retrovirus-based vector RCAS(B) to express
foreign genes in the spinal cord, because we favored the relatively
weak promoter activity of this vector to avoid ‘‘super physiologi-
cal levels’’ of expression.
NcoI site including initiation codon, Myc-tag sequence, and
Csp45I site were added in frame with 50-end of NeuroM-coding
sequence with a primer 50–CCATGGAGCAGAAACTCATCTCTGAA-
GAAGAAGATCTTCGAACGAAGACGTACACCAAAGCCAAGG-30, and
so was Spe I site after the stop codon of NeuroM cDNA by PCR
using Pfu DNA polymerase. The PCR product was cloned into
pCRII TOPO Blunt (Invitrogen) and was sequenced. Following
digestion with NcoI and SpeI, NeuroM-coding region with Myc-
tag was transferred to the Slax13-NcoI adapter vector in which
the original PstI site was replaced with SpeI site in advance. ClaI
fragment containing the expression cassette was then transferred
to RCAS(B) vector (Hollenbeck and Fekete, 2003).
For the construction of Nuc-GFP, Ngn2, Ascl1, and Ptf1a
expression vector, NeuroM-RCAS(B) vector was pre-digested with
Csp45I and SpeI to remove NeuroM cDNA, but to leave Myc-tag
sequence in the RCAS(B) vector. Csp45I site was added to the 50-
end of coding sequence of Nuc-GFP, Ngn2, Ascl1 and Ptf1a by PCR
in frame with Myc-tag sequence. Stop codon and SpeI site were
also added to the 30-end of the coding sequences. The PCR product
with the Csp45I and SpeI sites was cloned into pCRII TOPO Blunt
vector, and was sequenced. Following the digestion of the cloned
vector by Csp45I and SpeI, the fragment was transferred to the
pre-digested NeuroM RCAS(B) vector. The primer pairs used for
the addition of Csp45I and SpeI sites were 50–TTCGAATGGTGAG-
CAAGGGCGCCG-30 and 50–ACTAGTTTATCTAGATCCGGTGG-30 for
Nuc-GFP, 50–TTCGAATGCCGGTGAAGGCGGAGAGCCCGGCGCCCGC
GGCG-30 and 50- ACTAGTTTAGAGGCAGCGGTGGGGCGGCGGCGG
CGGGGCG-30 for Ngn2, 50–TTCGAAGTGCCAGCGGCAGCCCCGCC
GGGATGGCC-30 and 50–ACTAGTTCAGAACCAGCTGGTGAAGTCGA-
GCAG-30 for Ascl1, and 50–TTCGAATCGACGCCGTACTCCTGGAG-
CACTTCCCCGGGGGCC-30 and 50–ACTAGTCAGGACACAAACTCA
AAGGGTGGTTCGTTCTCTATGTTG-30 for Ptf1a. For high levels of
Ngn2 expression, Myc-tagged Ngn2 cDNA was ampliﬁed by PCR,
and the resulting PCR product was ligated to pCAGGS vector
(generous gift from Dr. Miyazaki: Niwa et al., 1991).
We have obtained two PCR products of chick engrailed1 cDNA,
the long and short form. For expression vector construction, we
have used the short form, in which 114 base pairs were deleted
from the long form. The DNA sequence that encodes the ﬁrst 215
amino acids containing the conserved repressor region of chick
engrailed1 protein was fused with cDNA sequence coding bHLH
domain of NeuroM, Ngn2, Ascl1, and Ptf1a by PCR-mediated
overlap extension. The PCR product was cloned into pCRII TOPO
Blunt vector (Invitrogen) and sequenced. After the correct
sequence was conﬁrmed, the vector was digested by Csp45I and
SpeI, and the fragment was transferred to the predigested
NeuroM RCAS(B) vector. The conserved repressor region was
ampliﬁed by PCR with a common 50-end primer with Csp45I site,
50–TTCGAATCGAAGAGCCGCCGGAGGGGCACGGCC-30 and gene
speciﬁc primers, 50–GCCTTGGTGTCCTCCTTCTCCGTCTTCTTCTTC-
30 for NeuroM, 50–CCGTCTCCGCGTCCTCCTTCTCCGTCTTCTTCTTC-
30 for Ngn2, 50–GCTGCGGGAGGTCCTCCTTCTCCGTCTTCTTCTTC-30for Ascl1, and 50–GTCCTCCTTCTCCGTCTTCTTCTTCTTCAGCTTCCT
GGTGC-30 for Ptf1a. Complementary DNA sequences coding bHLH
domain of NeuroM, Ngn2, and Ascl1 were ampliﬁed, and simul-
taneously SpeI site was added at the 30-end by PCR with primer
pairs, 50–GAGAAGGAGGACACCAAGGCCAGGTTGGAGAGGTTCAGG
GCTCGG-30 and 50–ACTAGTCTACTTCCCTTCCGGGGTCTGCCCCGT
TTC-30 for NeuroM, 50–GAAGGAGGACGCGGAGACGGCGCAGCG-
CATCAAGC-30 and 50–ACTAGTCTAGATGTAGTTGTGGGCGAAGCG-
CAGCG-30 for Ngn2, and 50–GAAGGAGGACCTCCCGCAGCAGCA
GCCCGCCGCCG-30 and 50–ACTAGTCTAGTACTCGACGGCGGAGCGCAG-
CGTC-30 for Ascl1. For Ptf1a, the sequence coding only bHLH domain,
but not RBPJk binding domain was ampliﬁed using 50–GAAGAA-
GACGGAGAAGGAGGACCGACGCGTGCGCTCCGAGGCGG-30 and 50–
ACTAGTTCAGCAGATGATAACCTTCTGGGCCTGGTTACCGGG-30.
To construct an expression vector for a fusion protein of VP16
activator domain with the amino terminal side of bHLH domain of
NeuroM and Pf1a, cDNA sequences coding the VP16 activator
domain was ampliﬁed using a common forward primer 50–TTCGAA-
TATCGACGGCCCCCCCGACCGATGTCAGC-30 and gene speciﬁc pri-
mers, 50–CCAACCTGGCCTTGGTCATCCCACCGTACTCGTCAATTCC-30
for NeuroM, and 50–GCGTCGCCGCCTTGCTGCCCCACCGTACTCGT-
CAATTCC-30 for Ptf1a. Complementary DNA sequences for NeuroM
bHLH domain was ampliﬁed with primers, 50–GGAATTGACGAG-
TACGGTGGGATTGACCAAGGCCAGGTTGG-30 and 50–ACTGTCATTTG-
CAGAGCATCTCCACG-30. DNA sequence for the Ptf1a bHLH and
RBPJk binding domain was ampliﬁed using primer pair, 50–TTCGAA-
TATCGACGCCCCCCCGACCGATG-30 and 50–GCGTCGCCGCCTTGCT
GCCCCACCGTACTCGTCAATTCC-30. To express an obligate activator
form of Ngn2 protein, we bonded the VP16 activator domain to the
carboxyl side of the Ngn2 bHLH domain. DNA sequence encoding
the bHLH domain of Ngn2 protein was ampliﬁed using primers, 50–
TTCGAAAGGGGCCCCCGCGGGCGGCGCGCACGGCGGAGACGGCGC-30
and 50–CGGGGGGGCCGTCGATATTCGGGCGGCCCCGGCCAGGCG-
CAGCG-30. The sequence for VP16 activator domain was ampliﬁed
with primers, 50–CGCTGCGCCTGGCCGGGGCCGCCCGAATATCGACGG
CCCCCCCG-30 and 50–ACTAGTCACCCACCGTACTCGTCAATTCCAAGG
GC-30. For a fusion protein of VP16 activator domain with carboxyl
terminal side of the bHLH domain of Ascl1, cDNA sequences coding
Ascl1 bHLH domain and VP16 activator domain were ampliﬁed




CAATTCCAAGGGC-30, respectively. Compatible pairs of PCR frag-
ments were fused by PCR. After the correct sequence was veriﬁed,
the fused fragment was transferred to predigested RCAS vector.
5-BrdU and EdU treatment
Fifty microlitter of 5-bromodeoxyuridine (5-BrdU) or 5-ethy-
nyl-20-deoxyuridine (EdU: 1 mg/ml in saline) was injected into
the amniotic sac one hour before sacriﬁcing embryos. Incorpo-
rated EdU was visualized by Click-iT EdU imaging kit (Invitrogen).
5-BrdU was immunohistochemically detected.
In situ hybridization
The lumbar portion of the embryo was placed in Tissu-Tek
media and fresh-frozen in dry ice-isopentane. Transverse sections
were cut and mounted on silane-coated slide glasses.
Digoxigenin-labeled RNA probes were synthesized from line-
arized cDNA templates. Hybridization was essentially carried out
as described in Homma et al. (2003). Brieﬂy, sections were
incubated with probes in 50% formamide, 5X Denhardt’s solution,
5X SSC for 16 h at 70 1C.
T. Shimada et al. / Developmental Biology 370 (2012) 250–263 253For double probe in situ hybridization, digoxigenin- and
ﬂuorescein-labeled RNA probes were simultaneously incubated
with sections. After post-hybridization washing, anti-digoxigenin
antibody immunohistochemistry was ﬁrst carried out, and BM-
purple substrate (Roche) was used as a substrate for conjugated
alkaline phosphatase reaction (blue reaction product). After the
alkaline phosphatase was inactivated by ﬁxing sections in 4%
paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) for
30 min, sections were again incubated in anti-ﬂuorescein anti-
body conjugated with alkaline phosphatase (Roche) overnight at
4 1C HNPP ﬂuorescent detection set (Roche) was used for the
second coloring reaction (red reaction product).
Immunohistochemistry and TUNEL
Embryos were ﬁxed in 4% PFA in 0.1 M PB for 30 min at 4 1C, and
immersed in 20% sucrose in 0.1 M phosphate buffered saline (PBS)
overnight. The lumbar region of the embryo was frozen-embedded.
Embryos were transversely sectioned (12 mm thickness).
Anti-neuron-speciﬁc nuclear protein antibody (NeuN) and
anti-neuron-speciﬁc isform of b-tubulin antibody (Tuj1) were
purchased from Chemicon and Promega, respectively. The mouse
monoclonal anti-Myc and anti-p27 antibodies were from Santa
Cruz and BD Bioscience, respectively. Anti-Lhx1/5 and anti-Islet-1
antibodies were obtained from the Developmental Studies Hybri-
doma Bank. The 5-BrdU antibody was from Seikagakukogyo
(Japan). Myc-tag and 5-BrdU immunohistochemistry was carried
out after in situ hybridization. Alkaline phosphatase reaction
product of in situ hybridization was ﬁxed in 4% PFA in 0.1 M PB
for 30 min before immunohistochemistry. For 5-BrdU immuno-
histochemistry, nuclear DNA was denatured in 2N hydrochloric
acid for 30 min at 37 1C. Sections were incubated in the primary
antibodies overnight at 4 1C, and then in Histoﬁne Simple Stain
HRP-conjugated secondary antibody (Nissui, Japan) or
ﬂuorescent-conjugated secondary antibodies for 1 h at a room
temperature. 3,30-Diaminobenzidine (DAB) was used as a chro-
mogen. For double detection of Myc-tag and p27, the biotinylated
anti-Myc mouse monoclonal antibody (Santa-Cruz) was used
after p27 immunohistochemistry.
TUNEL reaction was carried out as described in Gavrieli et al.
(1992).
Quantiﬁcation and statistical analysis
For quantiﬁcation of Ngn2, NeuroM, and GFRa-positive cells,
nuclei present within in situ hybridization-positive areas were
counted in ﬁve to seven sections per embryo under camera lucida
drawing tube. NeuN-, Islet-1-, Lhx1/5-, p27-, and EdU-positive
nuclei were counted in captured digital images of ﬁve to seven
sections per embryo. For all cases, statistics were derived from ﬁve
embryos in total and were presented as the meanþstandard error of
the mean (SEM). One-sided t-test was used for comparison.Results
Parallel expressions of GFRa1 and bHLH genes
In the chick embryo spinal cord on embryonic day 3.5 (HH
stage 20-21), GFRa1 mRNA expression was observed along the
most medial margin of the mantle layer. GFRa1-positive cells
were segregated into two groups, a small cluster in the dorsal
region and a longitudinal stripe running dorsoventrally. A small
number of GFRa1-positive cells were scattered between these
two groups (Fig. 1A). Slightly later (embryonic day 4, E4, HH stage
24), apparent motoneurons expressed GFRa1 mRNA in theperiphery of the ventral spinal cord, in addition to the above
medial two expression domains (Fig. 1B). The localization of
GFRa1 mRNA overlapped with the region containing a pan-
neuronal marker (a neuron-speciﬁc isoform of b-tubulin, Tuj-1:
Fig. 1B), but was largely excluded from cells that contained nuclei
that had incorporated the thymidine analog (EdU), indicating that
GFRa1-expressing cells are postmitotic neurons (Fig. 1C).
This characteristic expression pattern of GFRa1 was very
similar to that of two basic helix-loop-helix (bHLH) transcrip-
tional factors, NeuroM (Math3, NeuroD4: Fig. 1D) and Neuro-
genin2 (Ngn2: Fig. 1E). Double in situ hybridization of GFRa1
mRNA with NeuroM or Ngn2 mRNA revealed that the expression
domains of GFRa1 corresponded closely to that of NeuroM and
Ngn2 along the dorsoventral axis although the expression domain
of NeuroM and Ngn2 were shifted towards the midline (Fig. 1F
and G). We partitioned the transverse plane of the unilateral
spinal cord into twenty segments along the dorsoventral axis and
quantiﬁed the number of GFRa1-, NeuroM-, and Ngn2-positive
cells within each segment, and found that they exhibited similar
distribution patterns (Fig. 1H). During development, the positions
of NeuroM and Ngn2 expression corresponded to that of GFRa1
(Suppl. Fig. 1).
Although GFRa4 expression was not a primary focus, it is of
interest that along the dorsoventral axis of the spinal cord, GFRa4
mRNA expression in the mantle layer matched that of a trans-
membrane Notch ligand, Delta1 in the ventricular layer (Fig. 1I
and J).
NeuroM function regulates the induction of GFRa1 expression
The above expression patterns suggest potential regulatory
roles for NeuroM and Ngn2 in the expression of GFRa1. To test
this possibility, we ﬁrst electroporated a NeuroM expression
vector into progenitor cells in the prospective lumbar spinal cord
at HH stage 14 (two days incubation). Under the promotor
activity of the retroviral long terminal repeat (LTR), the expres-
sion of GFP protein with Myc-tag and nuclear localization signal
(Myc-Nuc-GFP) was observed mainly in the nuclei of proliferating
ventricular cells and in some apparent differentiated neurons
(Fig. 2A). Because NeuroM mRNA and protein are normally
expressed in cells during the transitional period from proliferat-
ing cells to nascent neurons in the spinal cord (Roztocil et al.,
1997; Bylund et al., 2003), NeuroM protein was precociously
overexpressed in our experimental condition.
Compared to no alterations in the expression of GFRa1 mRNA
after Nuc-GFP overexpression (Fig. 2A), excess expression of
NeuroM protein in progenitor cells spatially and quantitatively
increased GFRa1 mRNA expression along the entire dorsoventral
axis of the lumbar spinal cord at HH stage 23–24 (approximately
2 day after electroporation: Fig. 2B and C). The distribution of
increased GFRa1 expression was not laterally restricted, but
also appeared even in the apparent ventricular layer (Fig. 2B).
To analyze the identity of the increased GFRa1-positive cells, we
pulse-labeled proliferating cell nuclei with EdU in the NeuroM-
transfected spinal cord at HH stage 19-20 (about 24 h after
electroporation) when progenitor cells are actively proliferating
in the most regions of the spinal cord. Myc-NeuroM-positive
nuclei appeared to be relatively concentrated, but were not
conﬁned to the lateral side of the spinal cord (Fig. 2D). We
examined ﬁve to seven sections from each of ﬁve transfected
spinal cords and never observed double-labeled nuclei with EdU
and Myc-NeuroM immunohistochemistry (Fig. 2D). We also
observed signiﬁcantly fewer EdU-positive nuclei after NeuroM
overexpression (Fig. 2D and E). However, the distribution and
number of cells expressing a marker for cell-cycle exit, p27kip1
(p27), were not changed at the same developmental stage (HH stage
Fig. 1. Parallel GFRa1, NeuroM, and Ngn2 expression in a subset of spinal neurons. (A) A transverse section of lumbar spinal cord at HH stage 21-22, showing in situ
hybridization of GFRa1. (B and C) Transverse sections from HH stage 24 spinal cord, showing double labeling of GFRa1 in situ hybridization and Tuj-1
immunohistochemistry in B, and double labeling of GFRa1 in situ hybridization (red) and EdU (green) in C. (D and E) NeuroM and Ngn2 in situ hybridization in
transverse sections of lumbar spinal cord at HH stage 21. Note the similar expression pattern to that of GFRa1 shown in A. (F and G) Double in situ hybridization of GFRa1
(blue) and NeuroM (red) in F, and of GFRa1 (blue) and Ngn2 (red) in G. Transverse sections are from the spinal cord at HH stage 21. (H) Distribution of GFRa1 (yellow line),
NeuroM (blue line), and Ngn2 (pink line)-positive cells along the dorsoventral axis. Horizontal axis: number of cells. Vertical Axis: twenty sectors along the dorsoventral
axis. (I and J) Delta1 in situ hybridization in I, and double in situ hybridization of GFRa4 (blue) and Delta1 (red) in J. Transverse sections are from HH stage 24 lumbar spinal
cord. In all micrographs, the outer boundaries and midlines of the spinal cord are circled by hatched lines.
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tions in the number and distribution of pan-neuronal makers
(neuron-speciﬁc nuclear protein: NeuN, or Tuj1) were observed at
a later developmental stage (e.g. HH stage 24) when the initial
neuronal distribution pattern was established (Fig. 2H and I, and not
shown). These results indicate that NeuroM biases progenitor cells
toward differentiation, but does not promote their exit from the cell
cycle. Taken together, it is likely that NeuroM overexpression
induced precocious expression of GFRa1 mRNA in differentiating
progenitor cells that are biased toward cell cycle exit. Moreover,
after the overexpression of NeuroM, GFRa2 and GFRa4 expression
was still observed, indicating that NeuroM does not override
endogenous subtype speciﬁcation programs for the expression of
other GFRa subtypes (Suppl. Fig. 2).
It is of interest to determine whether the expression of Ret, a
signaling component for GFRa1, is concomitantly upregulated
after the overexpression of NeuroM. However, the expression of
Ret in the spinal cord was reduced after NeuroM overexpression,
indicating that NeuroM transcriptional factor is also involved inthe regulation of Ret expression, albeit the mode of its action for
Ret is different from that for GFRa1 in the spinal cord (Suppl.
Fig. 3A).
Upregulation of GFRa1 mRNA expression following NeuroM
overexpression might be indirectly mediated by homeodomain-
containing factors that are expressed in the microdomains of the
spinal cord. However, as previously shown, excess NeuroM
expression does not alter the distribution or numbers of Islet-1-
postive nuclei in the ventral spinal cord even though it induces
ectopic GFRa1 mRNA expression in that region (Lee and Pfaff,
2003: Suppl. Fig. 3B and D), and Lhx1/5 expression was altered
only in a speciﬁc microdomain in the dorsal spinal cord (Suppl.
Fig. 3C and D). Thus, it is unlikely that increased GFRa1 mRNA
expression in the entire spinal cord is an integration of local
upregulation that is mediated by changes in the expression
of homeodomain factors in the microdomain after NeuroM
overexpression.
We next examined the effect of the suppression of NeuroM
function on GFRa1 mRNA expression. To repress NeuroM activity,
Fig. 2. Regulation of GFRa1 expression by NeuroM. (A) No alteration of GFRa1 in situ hybridization after the overexpression of nuclear-localized GFP with Myc-tag
(Myc-Nuc-GFP: brown precipitate in the right side of the spinal cord), as shown in a transverse section of the lumbar spinal cord at HH stage 24. (B) Increased GFRa1
in situ hybridization following NeuroM overexpression (brown precipitate) in the right side of the spinal cord. (C) Quantiﬁcation of GFRa1-positive cells in the Myc-
Nuc-GFP-overexpressed side (Control) and in the NeuroM-electroporated side of the spinal cord. ***po0.001. (D and E) No incorporation of EdU (red) into exogenous
NeuroM-positive nuclei (green Myc-tag immunohistochemistry) in D. In E, signiﬁcant decrease of EdU-positive nuclei, compared to the contralateral (Contra.) side.
**po0.01. (F and G) No changes in the distribution or number of p27-positive nuclei (red) at HH stage 19-20, following NeuroM overexpression (green nuclei). (H and I)
No changes in the distribution or number of NeuN-positive nuclei (red) at HH stage 24. Blue nuclei in H are Myc-tag immunohistochemistry. (J to L) The expression of
GFRa1 in J, of GFRa2 in K, of GFRa4 in L after NeuroM-EnR overexpression (brown nuclei) in the right side of the spinal cord at HH stage 24. Note the speciﬁc loss of
GFRa1 expression. (M) Quantiﬁcation of GFRa1-, GFRa2-, GFRa4-positive cells. **po0.01. (N and O) NeuN (red nuclei) distribution and quantiﬁcation following the
overexpression of NeuroM-EnR (blue nuclei). ***po0.001. (P) No apparent increase of apoptotic nuclei (TUNEL: red). Blue nuclei are Myc-tag immunohistochemistry for
NeuroM-EnR.
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the bHLH domain of NeuroM with the repressor domain of chick
engrailed1 protein (NeuroM-EnR). The NeuroM-EnR construct
was then electroporated into ventricular cells in the lumbar spinal
cord at HH stage 14. As revealed by the immunohistochemistry
for Myc-tag, NeuroM-EnR protein was translocated into the
nuclei, and the number of GFRa1 mRNA-expressing cells was
signiﬁcantly decreased two days after electroporation (Fig. 2J and
M). By contrast, the expression pattern and number of the other
two GFRa mRNA-expressing cell types were not altered, indicat-
ing speciﬁc loss of GFRa1-postive cells after the suppression
of NeuroM activity. (Fig. 2K, L, and M). The number, but not
distribution, of NeuN–positive nuclei was signiﬁcantly reducedafter the overexpression of NeuroM-EnR protein (Fig. 2N and O).
TUNEL-positive nuclei (dying cells) did not appear to be increased
after the expression of excess NeuroM-EnR protein (Fig. 2P).
These results show that the loss of GFRa1 expression after
NeuroM-EnR overexpression is due to the abrogation of neuronal
differentiation speciﬁc to the GFRa1 mRNA-expressing neuronal
lineage.
The overexpression of an obligate activator form of NeuroM
(NeuroM bHLH domain fused with the viral VP16 activator
domain) barely induced aberrant GFRa1 expression although
the slight extension of GFRa1 expression domain into the
normally GFRa1-sparse region in the dorsal spinal cord. This
suggests, together with the effect of NeuroM-EnR, that NeuroM
T. Shimada et al. / Developmental Biology 370 (2012) 250–263256may work as a transcriptional activator for an intermediate
target gene involved in the regulation of GFRa1 expression
(Suppl. Fig. 3E).
Changing the normal level of Ngn2 activity leads to aberrant
induction of GFRa1 expression
We next analyzed the regulatory role of Ngn2 in GFRa1
expression. For this purpose we electroporated an expression
vector coding the normal form of Ngn2 protein into the prospec-
tive lumbar spinal cord at HH stage 14. Two days after the
electroporation, Ngn2 overexpression spatially and quantitatively
increased GFRa1 mRNA expression, but not the number or
distribution of post-mitotic pan-neuronal markers (NeuN and
Tuj-1: Fig. 3A, B, C, D, and not shown.). Although previous studies
have demonstrated an increase of neuronal markers after Ngn2
overexpression in the spinal cord (Mizuguchi et al., 2001; Novitch
et al. 2001; Bylund et al., 2003; Lee and Pfaff, 2003), we have not
observed this using a RCASB vector. However, the expression of
ectopic and increased neuronal markers were induced after the
overexpression of Ngn2 using pCAGG vector, the promotor
activity of which is much stronger than that of the viral LTR in
RCAS vector (Niwa et al., 1991: Suppl. Fig. 4A). This indicates that
a subtype speciﬁc marker (e.g. GFRa1) vs. a general neuronal
marker requires different levels of Ngn2 expression. One day after
the electroporation (HH stage 20), Ngn2-expressing (Myc-tag-
positive nuclei) cells were concentrated in the lateral side of the
spinal cord, and signiﬁcantly fewer nuclei incorporated a thymi-
dine analog, EdU (Fig. 3E and F). Nevertheless, consistent with
there being no alteration of NeuN-positive cell numbers at HH
stage24, Ngn2 did not promote the cell cycle exit of progenitor
cells, as shown by no changes in the number of p27-positive
nuclei one day after the Ngn2 overexpression (HH stage 20:
Fig. 3G and H). Thus, Ngn2 overexpression using the RCAS
expression vector drove the cell cycle progression toward term-
inal differentiation, but never promoted exit from the cell cycle.
Notably all these data indicate that increased GFRa1 expression
by Ngn2 may be attributed to the precocious expression of GFRa1
in differentiating neuronal progenitor cells, but not to the over-
production of GFRa1-positive neurons. In addition to the altera-
tions of GFRa1 expression, GFRa2 expression was also changed
after Ngn2 overexpression. This suggests that the expressions of
other GFRamay be also regulated by bHLH factors including Ngn2
(Suppl. Fig. 2).
We next electroporated a construct expressing a repressor
form of Ngn2 protein (Ngn2-EnR), in which the bHLH domain of
Ngn2 was fused with the repressor domain of engrailed1
protein, into the lumbar spinal cord at HH stage 14, and GFRa1
mRNA expression pattern was examined at HH stage 24
(approximately two days after the transfection). Similar to the
overexpression of Ngn2 protein, Ngn2-EnR also increased GFRa1
expression (Fig. 3I and K). In the dorsal telencephalon, Ngn2
restricts Ascl1 (Mash1) expression in the dorsal telencephalon
(Fode et al., 2000), and similarly the overexpression of the
normal form of Ngn2 in the spinal cord suppressed Ascl1
expression whereas the introduction of our repressor form of
Ngn2 increased Ascl1 expression, indicating that the repressor
form of Ngn2 protein is functional (Suppl. Fig. 4B and C). Ngn2-
EnR overexpression did not change the number of NeuN-positive
nuclei (Fig. 3J and K) and neither the incorporation of EdU or p27
expression was altered following Ngn2–EnR overexpression (not
shown). Currently, the identity of cells that ectopically express
GFRa1 mRNA is unclear.
Because both Ngn2 and Ngn2-EnR overexpression increased
GFRa1 expression, endogenous Ngn2 may work as a transcrip-
tional repressor for the expression of target genes involved in theregulation of GFRa1 expression. However, the overexpression of
an obligate activator form of Ngn2 (Ngn2-VP16), which is a fusion
protein of the bHLH domain of Ngn2 and VP16 activator domain
of human herpesvirus, also resulted in the increased GFRa1
expression (Fig. 3 L and N). Nevertheless, Ngn2-VP16 overexpres-
sion suppressed Ascl1 expression in the spinal cord, similarly to
Ngn2, indicating that our Ngn2-VP16 properly functions as a
transcriptional repressor (Suppl. Fig. 4D). Thus, Ngn2 does not
normally act as a simple transcriptional repressor for GFRa1
expression. Taken together with the above results, we hypothe-
sized that a certain level of Ngn2 expression may be necessary for
the proper expression of GFRa1 mRNA. Any deviation from an
optimum level of Ngn2 expression may result in aberrant GFRa1
expression. On the contrary to no change in general neuronal
production after Ngn2 overexpression, Ngn2-VP16 marginally but
signiﬁcantly increased neuronal production as indicated by the
increased number of NeuN-positive nuclei (Fig. 3 M and N). This
also supports the above result that different levels of Ngn2
expression are required to differentiate between general and
subtype-speciﬁc neuronal speciﬁcation.
Consistent with an inductive role of NeuroM in GFRa1 expres-
sion, NeuroM mRNA expression was upregulated after Ngn2,
Ngn2-EnR and Ngn2-VP16 overexpression (Fig. 3O, P, and Q).
Suppression of Ngn2 expression by Ascl1 leads to ectopic GFRa1
expression
Ascl1 is expressed in a complementary fashion to Ngn2 in
many regions of the central nervous system. In the dorsal spinal
cord of the chick embryo, Ngn2 and Ascl1 mRNA expression
appear mutually exclusive, suggesting a possible inhibitory reg-
ulation between Ascl1 and Ngn2 (Suppl. Fig. 5A, B, and C).
Although the suppression of Ascl1 expression by Ngn2 has been
well documented, the overexpression of Ascl1 also diminished
Ngn2 mRNA expression in retinal progenitor cells (Fode et al.,
2000; Mao et al., 2009; Roybon et al., 2010). In our study,
electroporation of an Ascl1 expression vector at HH stage 14 also
resulted in the apparent reduction of Ngn2 mRNA expression
(Fig. 4A). We have not been able to determine whether this
reduction is owing to the direct suppression of Ngn2 expression
by Ascl1, or to increased numbers of progenitor cells in which
Ngn2 expression has been permissively reduced by Ascl1. How-
ever, the reduction ascribed to the narrowing expression
domains, rather than to loss of Ngn2 mRNA expression, suggests
an increase of Ngn2-negative progenitor cells (Fig. 4A). We next
analyzed the effect of lowering Ngn2 expression levels on GFRa1
by overexpression of Ascl1.
As expected from elevated GFRa1 expression after the sup-
pression of Ngn2 activity, the downregulation of Ngn2 expression
by Ascl1 overexpression also resulted in spatial and quantitative
up-regulation of GFRa1 mRNA expression in the spinal cord at
stage HH 23-24, regardless of the location of endogenous Ascl1
expression (Fig. 4B and C, and Suppl. Fig. 5). GFRa1 mRNA
expression appeared to be segregated from the localization of
5BrdU-positive nuclei and to be conﬁned within the mantle layer,
suggesting increased production of GFRa1 mRNA-positive neu-
rons (Fig. 4B and D). This is quite different from the localization of
GFRa1 expression following the overexpression of NeuroM, which
is coincident with 5-BrdU-positive nuclei (not shown, but com-
pare Fig. 4B to Fig. 2B). Nevertheless, Ascl1 overexpression
signiﬁcantly reduced the total number of NeuN-positive nuclei
at HH stage 23-24 (Fig. 4E and F). In addition, the absence of
commissural ﬁbers made the electroporated side of the spinal
cord appear smaller than normal (Fig. 4E and not shown). It is
somewhat puzzling that the effect of Ascl1 overexpression
decreased neuronal production whereas GFRa1-positive neurons
Fig. 3. Ngn2 overexpression promotes GFRa1 expression. (A and B) Increased GFRa1 in situ hybridization at HH stage 24 after Ngn2 overexpression (brown precipitate) in
A. GFRa1–positive cells are signiﬁcantly increased in B. ***po0.001. (C and D) No change of NeuN-positive nuclei (red) in distribution in C (HH stage 24: blue ﬂuorescence,
Myc-tag immunohistochemistry) and in numbers in D. (E and F) Lateral concentration and no EdU incorporation (red) of Ngn2-positive nuclei (green) at HH stage 20 in E.
Signiﬁcant reduction in the number of EdU-incorporated nuclei (***po0.001), compared to the contralateral side (Contra.) in F. (G and H) p27-positive nuclei are
unchanged in the distribution (red) in G and in number in H at HH stage 20. The overexpression of both obligate suppressor and activator forms of Ngn2 promote GFRa1
expression. (I and J) Upregulation of GFRa1 in situ hybridization after Ngn2-EnR overexpression at HH stage 24 in I. No change in the distribution of NeuN-positive nuclei
(red) in J. Brown or blue nuclei, Myc-tag immunohistochemistry for Ngn2-EnR. (K) Quantiﬁcation of GFRa1-positive cells and NeuN-positive nuclei. ***po0.001.
(L to N) GFRa1 in situ hybridization is upregulated even after Ngn2-VP16 overexpression (brown nuclei) at HH stage 24 in L. The number of NeuN-positive nuclei (green) is
increased after Ngn2-VP16 overexpression (red) in M. In N, ***po0.001 and *po0.05. (O to Q) NeuroM in situ hybridization at HH stage 24 after Ngn2, Ngn2-EnR, and
Ngn2-VP16 overexpression in O, P, and Q, respectively.
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Fig. 4. The downregulation of Ngn2 expression by Ascl1 increases GFRa1 expression. (A) The reduction of Ngn2 in situ hybridization after Ascl1 overexpression (brown
precipitate) in the right side of the spinal cord at HH stage 24. (B and C) Signiﬁcant increase of GFRa1 in situ hybridization in the right side of the spinal cord at HH stage 24
in B. In C, ***po0.001. (D) Increased GFRa1 in situ hybridization is restricted to the mantle layer (m) and is segregated from 5-BrdU immunohistochemistry (brown) in the
ventricular layer (v) in the electroporated side (right). (E and F) Decreased NeuN-positive nuclei (red) two days after Ascl1 overexpression (blue) in the right side of the
spinal cord at HH stage 24 in E. ***po0.001 in F. (G and H) Ectopic p27-positive nuclei (red in the right side) after Ascl1 overexpression (green) at HH stage 18 in G, and
signiﬁcant increase of the number of p27-positive nuclei, compared to the contralateral (Contra.) side in H (***po0.001). (I and J) No overlapping of EdU-positive nuclei
(red) with Ascl1-positive nuclei (green), which are laterally located in HH stage 19 spinal cord. In J, ***po0.001. (K) Reduced NeuroM in situ hybridization. Overexpression
of Ascl1-EnR abolishes neuronal differentiation without arresting cell cycle progression. (L to O) The loss of GFRa1 in situ hybridization in L and NeuN-positive nuclei (red)
in N two days after electroporation of Ascl1-EnR construct (brown or blue nuclei of Myc-tag immunohistochemistry). In M and O, ***po0.001.
(P and Q) The induction of ectopic p27-positive nuclei (green) one day after Ascl1-EnR overexpression (HH stage 19: red nuclei in the right side) in P and the number
is signiﬁcantly increased, compared to that in the contralateral side (Contra.) in Q (*po0.05). (R and S) The percentage of EdU-incorporated nuclei (red) among Ascl1-EnR-
positive nuclei (green) is signiﬁcantly increased, compared to that of EdU-incorporated nuclei among Nuc-GFP-positive nuclei in the control spinal cord. Only the
electroporated side of the spinal cord at HH stage 19 is shown in R. In S, ***po0.001. (T and U) Reduction of NeuroM and Ngn2 in situ hybridization at HH stage 24.
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electroporation of Ascl1 (HH stage 18-19), we observed: (1)
more and more ectopic p27-positive nuclei (Fig. 4G and H); (2)
lateral localization of Myc-tag (Ascl1-expressing nuclei:Fig. 4I); and (3) lower incorporation of EdU (Fig. 4I and J). These
data demonstrate that Ascl1 promotes neurogenesis. Because
Ascl1 overexpression did not increase apoptotic nuclei (not
shown), we reasoned that Ascl1 overexpression may accelerate
T. Shimada et al. / Developmental Biology 370 (2012) 250–263 259cell cycle exit of progenitor cells and hence deplete the progenitor
reservoir, eventually leading to production of fewer neurons.
From this, we suggest that the increase of GFRa1 mRNA expres-
sion is ascribed to the relative expansion of GFRa1-positive
neuronal production. Ascl1 overexpression also reduced GFRa2,
but not GFRa4 (Suppl. Fig. 2).
As previously shown, NeuroM expression is closely associated
with that of GFRa1. However, NeuroM mRNA expression was
downregulated following Ascl1 overexpression although Ascl1
increased GFRa1 expression. Like Ngn2 following Ascl1 over-
expression, this downregulation of NeuroM also appears to be
due to narrowing the expression domain, and not to the loss of
expression (Fig. 4K). Taken together with the previous results, this
downregulation of NeuroM indicates that NeuroM is sufﬁcient,
but not necessary for GFRa1 expression. Thus, NeuroM is not a
direct inducer for GFRa1 expression.
Although the above results clearly demonstrate that Ascl1
alone is sufﬁcient for GFRa1 expression, the onset and expression
pattern of Ascl1 is not related to that of GFRa1 (Suppl. Fig. 5B, C,
D, E, and F). This difference suggests that Ascl1 may compete and
intervene in the regulatory sequence of a distinct determinant
involved in GFRa1 expression, rather than Ascl1 itself working as
a direct speciﬁcation factor by binding its own speciﬁc target
sequence for transcription. This possibility was examined in the
next experiment, in which Ascl1 function was blocked by the
introduction of an expression vector carrying the suppressor form
of Ascl1 (Ascl1-EnR). Ascl1-EnR electroporation at HH stage 14
abolished the markers of neuronal differentiation including
GFRa1 mRNA (Fig. 4L and M), NeuN (Fig. 4N and O), and Tuj1
(not shown) expression. This suppression occurred even in the
region, in which endogenous Ascl1 expression was not observed,
thus demonstrating the presence of a different determinant for
GFRa1 expression, which Ascl1 can competitively modify.
Furthermore, after the overexpression of an obligate activator
form of Ascl1 (Ascl1-VP16), GFRa1 expression was also dimin-
ished regardless of endogenous Ascl1-expression domain (Suppl.
Fig. 6A). Ngn2 expression appeared not to be largely affected
(Suppl. Fig. 6B). Since the dominant activator form of Ascl1
reversed the effect of Ascl1, Ascl1 may act as a competitive
transcriptional repressor for the target gene of a putative deter-
minant for GFRa1 expression in the normal context of GFRa1
differentiation.
One day after electroporation of Ascl1-EnR, more and more
ectopic p27-positive nuclei were observed (HH stage 19: Fig. 4P
and Q). The number of progenitor cells passing through the S-
phase was also signiﬁcantly increased, as shown by increased
ratio of double-labeled nuclei with Ascl1-EnR (Myc-tag) and EdU/
Ascl1-EnR-positive nuclei, compared to that of Nuc-GFP- and
EdU-double positive nuclei/Nuc-GFP-positive nuclei (Fig. 4R and
S). Thus, the suppression of Ascl1 function acceralates cell cycle
progress and exit. Apoptosis was not increased after the suppres-
sion of Ascl1 activity (not shown). These data indicate that
abrogated neuronal differentiation, including GFRa1 expression
following the overexpression of Ascl1-EnR, is due to the direct
suppression of neuronal phenotype expression, rather than to
arresting the progression of the cell cycle or to inducing cell death
of progenitor cells. Moreover, these data further indicate that two
aspects of the neurogenic function of Ascl1 are separable: Ascl1 is
necessary for the expression of GFRa1 neuronal subtype, but is
unnecessary for cell cycle exit.
The expression of NeuroM and Ngn2 mRNAwere also abrogated
by the overexpression of Ascl1-EnR (Fig. 4T and U). Thus, the
suppression study using Ascl1-EnR further supports an epistatic
role of Ascl1 over Ngn2 downregulation: Ascl1 may act at an earlier
time window to permissively downregulate Ngn2 expression
during the differentiation of progenitor cells.Promoting Ngn2 expression by Ptf1a induces ectopic GFRa1
expression
We next asked whether increasing Ngn2 expression by other
transcriptional factors might also induce aberrant GFRa1 expression.
A recent study has demonstrated that a bHLH transcriptional factor,
pancreatic transcriptional factor 1a (Ptf1a), is a direct transcriptional
activator of Ngn2 genes in the dorsal spinal cord (Henke et al., 2009).
When we overexpressed Ptf1a in the chick embryo spinal cord by
electroporation at HH stage 14, an upregulation of Ngn2 mRNA was
observed at HH stage 24 in both dorsal and ventral spinal cord
(Fig. 5A). Concomitantly, GFRa1 expression was also spatially and
quantitatively upregulated in the apparent mantle layer of the entire
spinal cord (Fig. 5B and C). Consistent with this, the localization of
increased GFRa1 expression did not overlap with 5-BrdU-labeled
nuclei, as observed after Ascl1 overexpression (not shown). How-
ever, one difference is that Ptf1a alone cannot promote the cell cycle
exit of progenitor cells. Rather, our results indicate that Ptf1a
appears to retard cell cycle progression: (1) Ptf1a overexpression
signiﬁcantly decreased p27-positive nuclei at HH stage 18 (Fig. 5D
and E) and NeuN-positive nuclei two days after electroporation
(Fig. 5F and G); nevertheless, (2) Ptf1a drove progenitor cells toward
cell cycle exit as indicated by lateral settlement of Myc-tag-positive
nuclei, the lack of incorporation of EdU into Myc-tag-positive nuclei,
and signiﬁcantly fewer EdU-positive nuclei (Fig. 5H and I). From
these data, we conclude that elevated levels of Ngn2 by Ptf1a led to
ectopic GFRa1 expression within a ﬁxed number of differentiated
neurons. Ptf1a also reduced the expression of GFRa2, as NeuroM,
Ngn2 and Ascl1 did (Suppl. Fig. 2).
The downregulation of Ptf1a activity using a suppressor form
of Ptf1a (Ptf1a-EnR) resulted in an effect similar to that after the
overexpression of Ascl1-EnR. The overexpression of Ptf1a-EnR
signiﬁcantly reduced the expression of neuronal markers includ-
ing GFRa1, NeuN, and Tuj1 expression without any apparent
increase in apoptosis (Fig. 5J, K, L, and not shown). NeuroM and
Ngn2 expression were also reduced (Fig. 5M and not shown). One
day after electroporation of the Ptf1a-EnR expression vector (HH
stage 20), the ratio of Ptf1a-EnR- and EdU-double positive nuclei/
Ptf1a-EnR-positive nuclei was signiﬁcantly increased, compared
to that of Nuc-GFP- and EdU-double positive nuclei/Nuc-GFP-
positive nuclei (Fig. 5N and O). Additionally, ectopic and signiﬁ-
cantly more p27-positive nuclei were observed (Fig. 5P and Q).
Thus, like Ascl1-EnR does, Ptf1a-EnR also inhibits neuronal
differentiation, but not cell cycle progression or exit.
As with Ascl1, the onset and expression pattern of Ptf1a doe not
match that of GFRa1, even though it has an ability to induce GFRa1
expression (Suppl. Fig. 7). The suppression of Ptf1a activity also
resulted in the abrogation of neuronal differentiation in the entire
spinal cord, as observed after Ascl1 overexpression. These data
indicate that Ptf1a may also competitively interact with a preexisting
determinant for GFRa1 expression similar to Ascl1. Being consistent
with this, Ptf1a-VP16 overexpression also resulted in the upregulation
of Ngn2 and GFRa1, regardless of endogenous expression pattern of
Ptf1a (Suppl. Fig. 6D and E). Thus, Ptf1a may act as a competitive
transcriptional activator for a GFRa1-determinat.Discussion
Developmental roles of GFRa1 in differentiating neurons
GFRa1 is expressed soon after the differentiation of neurons in
the spinal cord. Because the axons of the nascent neurons have
not reached their targets, GFRa1 plays a different role from
canonical trophic function involving target-derived neurotrophic
factors. In the ventral forebrain, GFRa1 participates in the
Fig. 5. Regulation of GFRa1 expression by Ptf1a. (A) The upregulation of Ngn2 expression in the entire right half of the spinal cord after the electroporation of Myc-Ptf1a
(brown nuclei). (B and C) Upregulation of GFRa1 expression at HH stage 24 by Ptf1a overexpression (brown nuclei). Note restricted GFRa1 expression within the mantle
layer of the spinal cord. In C, ***po0.001. (D to G) Decreased p27-positive nuclei (red) one day after the electroporation in D. In E, *po0.05. NeuN-positive nuclei (red) are
also reduced two days after electroporation in F. In G, **po0.01. (H and I) Lateral settlement of Ptf1a-expressing nuclei (green) and segregation from EdU-labeling (red) at
HH stage 20. In E, signiﬁcant reduction of EdU incorporation (***po0.001). (J to L) Decreased GFRa1 in situ hybridization in J and NeuN-positive nuclei (red) in I at HH stage
24 after Ptf1a-EnR overexpression (brown or blue nuclei). In L, ***po0.001. (M) Reduced Ngn2 in situ hybridization. (N and O) Incorporation of EdU (red) in Ptf1a-EnR-
positive nuclei (green). Only the electroporated side of the spinal cord at HH stage 20 is shown in N. In O, signiﬁcant increase in the ratio of the number of Ptf1a-EnR
(green)- and EdU (red)-double positive nuclei to that of Ptf1a-EnR-positive nuclei, compared to the number of GFP-Nuc- and EdU-double positive nuclei to that of GFP-
Nuc-positive nuclei. ***po0.001 in O. (P and Q) Ectopic p27-positive nuclei (red) are induced one day after electroporation of Ptf1a-EnR (green nuclei) in P. In Q, signiﬁcant
increase of p27-positive nuclei (*po0.05).
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interneurons via Ret- and NCAM-independent manner after the
production of cortical inhibitory interneurons is determined by
Ascl1 (Pozas and Iba´n˜ez, 2005; Canty et al., 2009). In the early
spinal cord, GDNF mRNA is detected in the ﬂoor plate (Homma
et al., 2000). Likewise in the spinal cord, GFRa1 may play a role in
the differentiation of a neuronal subpopulation, or migration of a
neuronal subpopulation, possibly by means of ligand-induced cell
adhesion (Ledda et al., 2007). From the view of an early develop-
mental role for GFRa1, we can not know which possibility early
GFRa1 expression reﬂects, that the GFRa1 expression in an
immature neuron is maintained even after the settlement in a
ﬁnal destination, or that GFRa1 expression is transient in nascent
neurons and after the migration to the ﬁnal locations, maturated
neurons re-express GFRa1.We demonstrated that the overexpression of bHLH factors
affected mainly GFRa2 expression and that GFRa4 expression is
related to a Notch ligand, Delta. These indicate that bHLH factors
and related molecules are also involved in the regulation of these
two receptor expressions. In this study, however, we focus on the
regulatory roles of bHLH factors for GFRa1.
NeuroM may act as a differentiation factor for the GFRa1 phenotype
Combinatorial actions of bHLH and homeodomain transcrip-
tional factors have been shown to control the local production of
speciﬁc classes of neurons in various regions of the nervous system
(Bertland et al., 2002). In the ventral spinal cord, NeuroM has no
effect on the differentiation of the neuronal subtype, but induces
motorneuron differentiation together with LIM-homeodomain
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in other regions of the spinal cord, where its role is unclear.
NeuroM is expressed during a transitional period between the
occurrence of undifferentiated neuronal progenitor cells and
differentiating immature neurons and thus may act to regulate
the differentiation of neuronal phenotypes (Roztocil et al., 1997;
Pleasure et al., 2000; Tomita et al., 2000). In the present study,
we have demonstrated in the chick embryo spinal cord that: (1)
the expression patterns of GFRa1 and NeuroM are very similar;
(2) the overexpression of NeuroM alone is sufﬁcient to induce
precocious expression of GFRa1 mRNA in differentiating pro-
genitor cells; and (3) NeuroM protein activity is required
speciﬁcally for the differentiation of the GFRa1 neuronal lineage.
All these results demonstrate that NeuroM may act as a differ-
entiation factor for the GFRa1 phenotype in the spinal cord.
However, it is unlikely that GFRa1 gene is a direct transcrip-
tional target of NeuroM protein. Our overexpression studies
demonstrate that NeuroM is required for the neuronal produc-
tion of GFRa1 subtype, but that NeuroM alone is not sufﬁcient
for this purpose, indicating that NeuroM is involved, together
with other differentiation factors, in promoting the maturation
of nascent GFRa1-positive neurons. Moreover, Ascl1 overexpres-
sion upregulates GFRa1 expression even though it decreases
NeuroM mRNA expression, indicating that NeuroM is sufﬁcient
but not essential for the induction of GFRa1 expression. Ascl1
may bypass the action of NeuroM in the induction of GFRa1
expression, or it may suppress the action of an inhibitory factor
in the regulatory machinery of GFRa1 expression. Thus, NeuroM
may be a constituent of the regulatory machinery for GFRa1
expression.
An appropriate level of Ngn2 expression is important for GFRa1
expression
Previous studies have extensively demonstrated that Ngn2
alone is sufﬁcient for general neuronal production, whereas, for
subtype speciﬁcation function, Ngn2 requires co-factors, which
are expressed in regionally restricted microdomains, ensuring
that fate speciﬁcation role of Ngn2 is separable from the general
proneural function (Bertrand et al., 2002; Guillemot, 2007). We
have asked how the GFRa1 phenotype, which is shared by
neuronal subpopulations localized in multiple microdomains in
the spinal cord, is speciﬁed. The results demonstrate that Ngn2
alone is sufﬁcient for this purpose, but that it requires optimal
levels of expression for proper GFRa1 speciﬁcation, and further
that variable levels of Ngn2 expression may separate fate speci-
ﬁcation from the proneural role of Ngn2. The exact nature and
levels of Ngn2 required for the correct differentiation of GFRa1 is
not clear from our study. Previous studies have shown that
ectopic expression of Ngn2 in progenitor cells of the ventral
forebrain differed, depending on the means of Ngn2 misexpres-
sion. In the ventral forebrain of the transgenic mouse in which
Ascl1 gene is replaced by Ngn2, no dorsal forebrain markers are
induced (Fode et al., 2000). However, in utero electroporation of a
Ngn2 expression vector induces dorsal forebrain makers in the
ventral forebrain (Mattar et al., 2008). In vitro transfer of Ngn2
gene in progenitor cells from the ventral forebrain also results in
the expression of dorsal neuronal markers (Roybon et al., 2010).
These differences may be ascribed to various expression levels of
Ngn2 driven by different promotor activities (Roybon et al., 2010).
Thus, in accord with our results, these data indicate that the level
of Ngn2 expression is important for subtype speciﬁcation.
A recent study has reported that Ngn2 expression in neuronal
progenitor cells is dynamic in that Ngn2 expression is oscillating
in progenitor cells in the developing mouse cortex and that a
sustained upregulation of Ngn2 may be necessary for neuronaldifferentiation (Kageyama et al., 2008; Shimojo et al., 2008). The
oscillation of another bHLH factor, Hes7 is also observed in
developing somites and serves as a segmentation clock
(Dubrulle and Pourquie´, 2004; Kageyama et al., 2007). Interest-
ingly, perturbations of this oscillation by loss of Hes7 activity or
by sustained expression of Hes7 result in the same phenotype of
fused somites (Bessho et al., 2001; Hirata et al., 2004). In our
study, both the promotion and suppression of Ngn2 activity also
led to aberrant GFRa1 expression. Although we have no idea
whether Ngn2 expression is oscillating in the chick embryo spinal
cord, we can only speculate that increased GFRa1 expression after
changing Ngn2 activity could reﬂect such a dynamic temporal
regulation of Ngn2.
A variety of extracellular and intracellular molecules regulate
the expression levels of Ngn2. During neurogenesis, Notch signal-
ing pathways negatively regulate Ngn2 expression levels,
whereas Wnt signaling pathways positively regulate Ngn2
expression (Backman et al., 2005; Hirabayashi et al., 2004; Yoon
and Gaiano, 2005; Machon et al., 2007). As shown in our study,
other bHLH factors (Ascl1 and Ptf1a) also regulate Ngn2 expres-
sion levels, directly or indirectly. Our study further demonstrates
that perturbation of Ngn2 expression levels affects the speciﬁca-
tion of GFRa1. These indicate that Ngn2 is not a direct inducer of
GFRa1 expression, but rather may serve as readout to control the
expression of other effector molecules that work as differentiation
factors for GFRa1. For the expression of GFRa1, integrated Ngn2
expression levels appear to be converted into a differentiation
program in which NeuroM is involved. Several previous studies
pointed out that NeuroM is downstream of Ngn2 in mouse cranial
sensory neurons, the retina, and the cortex (Fode et al., 1998;
Akagi et al., 2004; Schuurmans et al., 2004; Mattar et al., 2008).
Our study has also shown that the upregulation of NeuroM occurs
together with the upregulation of GFRa1 expression following the
perturbation of Ngn2. Because perturbation of Ngn2 expression
always led to the upregulation of GFRa1 in our study, there must
be a certain point where GFRa1 expression is negatively regu-
lated. In this regard, myeloid translocation gene related-1 protein,
MTGR1 is of interest. MTGR1 is expressed in a similar manner to
NeuroM, and MTGR1 suppresses NeuroM (Aaker et al., 2009).
Possible regulatory roles of Ascl1 and Ptf1a in GFRa1 expression
In the central and peripheral nervous system, Ascl1 has been
shown to act as a neuronal-subtype speciﬁcation factor (Bertrand
et al., 2002). The misexpression of Ascl1 induces ventral neuronal
makers in the dorsal forebrain (Fode et al. 2000) and Ascl1 also
induces noradrenergic differentiation in the sympathetic neuro-
nal lineage (Lo et al., 1998). Because the subtype-speciﬁcation
activity of Ascl1 is always associated with one particular neuronal
phenotype depending on the region of the nervous system, the
action of Ascl1 is context-speciﬁc. Our overexpression study
demonstrates that Ascl1 induces GFRa1 expression in the spinal
cord, regardless of the localization of endogenous Ascl1 expres-
sion. Therefore, the speciﬁcation function of Ascl1 for GFRa1 is
not coupled with co-factors regionally expressed at the site of
endogenous Ascl1 expression, but is highly likely to associate
with a more generalized context in the spinal cord.
Misexpression of Ptf1a in the dorsal telencephalon induces a
ventral phenotype, which also occurs after dorsal expansion of
Ascl1 in the telencephalon of Ngn2-mutant mouse (Fode et al.,
2000; Parras et al., 2002; Hoshino et al., 2005). In our study, the
overexpression of Ptf1a also mimics the effect of Ascl1 over-
expression with regard to the upregulation of GFRa1. Our results
demonstrate that Ascl1 is necessary but not sufﬁcient for Ptf1a
expression (Wildner et al., 2006: Suppl. Fig. 7C and D). These data
indicate that Ptf1a may act together with Ascl1 as a speciﬁcation
T. Shimada et al. / Developmental Biology 370 (2012) 250–263262or determination factor for GFRa1-positive neuronal subtype.
Expression patterns of Ascl1 and Ptf1a indicate that this may
occur during a limited spatial and temporal window. However,
similar to Ascl1, Ptf1a also has the ability to induce GFRa1 in
spinal cord regions lacking endogenous Ptf1a. This indicates that
Ptf1a is more likely to interact with a common regulatory
program for GFRa1 expression in the spinal cord, rather than
directly acting with Ascl1 in a speciﬁc location.
When two different transcriptional factors competitively bind
to a common regulatory target such as an enhancer region of
DNA, the deletion of one factor results in no changes in phenotype
because of compensatory binding by the other factor. By contrast,
the overexpression of a repressor form, which is composed of the
engrailed repressor domain and bHLH DNA-binding domain,
results in the total loss of downstream function because of full
occupation of the binding site by the repressor acting as a
dominant negative. This is what we observe in our overexpression
experiments using the suppressor forms of Ascl1 and Ptf1a (Ascl1/
Ptf1a). Interestingly, even in the regions of the spinal cord where
no Ascl11/Ptf1a is endogenously expressed, the overexpression of
the suppressor forms of Ascl1/Ptf1a abrogates neuronal differ-
entiation including GFRa1 expression. This clearly points to the
presence of a distinct determinant for GFRa1 expression, the
target sequence of which the binding domain of Ascl1/Ptf1a can
competitively perturb, although the identity of this competitive
determinant is not currently clear. Further evidence for a dis-
tinctive determinant comes from the fact that the overexpression
of both normal and suppressor forms of Ascl1 resulted in the
downregulation of Ngn2 expression. Although this appears con-
tradictory, it could also occur if the suppressor works as a
dominant negative form to antagonize the function of a compe-
titive determinant. Thus, Ngn2 is apparently positioned down-
stream of this competitor in the regulatory transcriptional
cascade for GFRa1 expression. Therefore, we do not favor the
idea that two different regulatory pathways (Ascl1/Ptf1a-depen-
dent and independent) for GFRa1 expression co-exist and work at
different developmental periods and cell lineages even though the
mismatch between Ascl1/Ptf1a and GFRa1 might so indicate.
Rather, we favor a model in which Ascl1/Ptf1a serve as compe-
titive modulators to stochastically alter default Ngn2 expression
levels in the regulation of GFRa1 expression.
We have demonstrated that Ascl1 suppresses Ngn2 expres-
sion, although the mechanism for this is not clear, and that Ascl1-
VP16 overexpression reversed this effect of Ascl1. Henke et al.
(2009) demonstrated that Ptf1a is a direct transcriptional activa-
tor of Ngn2 expression and we have also shown that both Ptf1a
and Ptf1a-VP16 overexpression upregulate Ngn2 expression
in vivo. These data indicate that Ascl1/Ptf1a may be counteracting
molecules for regulating the level of Ngn2 expression and there-
fore may modulate pre-existing levels of Ngn2, depending on how
much Ascl1/Ptf1a is available at a particular time and places. Our
results also show the appropriate levels of Ngn2 is critical for
GFRa1 expression. Changing the default levels of Ngn2 may lead
to variable levels of GFRa1 expression. Even very subtle changes
of Ngn2 expression could result in signiﬁcant changes of GFRa1,
ultimately leading to the creation of regional and temporal
differences in GFRa1 expression in the spinal cord. It is important
to identify determinants for default Ngn2 expression, with which
Ascl1/Ptf1a may cooperate in the spinal cord.
Finally, the role of Ascl1 in GFRa1 expression in the embryonic
spinal cord is reminiscent of the close link of the polymorphism in
Ascl1 protein to the susceptibility to Parkinson’s disease, although
it is not clear whether these bHLH factors are also involved in the
regulation of GFRa1 expression in adult DA neurons, the survival
of which in the adult CNS is supported by GDNF (Ide et al., 2005;
Pascual et al., 2008; Deng et al., 2010).Acknowledgment
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